Cantor Fitzgerald set a $19.00 price objective on Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note published on Tuesday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other analysts also recently issued reports on MRNS. Zacks Investment Research downgraded shares of Marinus Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, November 2nd. BidaskClub downgraded shares of Marinus Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Tuesday, October 9th. ValuEngine raised shares of Marinus Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, October 16th. Finally, Mizuho reaffirmed a buy rating and set a $13.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. Marinus Pharmaceuticals currently has an average rating of Buy and an average target price of $19.67.

Shares of NASDAQ MRNS opened at $4.52 on Tuesday. The stock has a market capitalization of $189.25 million, a price-to-earnings ratio of -5.65 and a beta of 3.18. Marinus Pharmaceuticals has a 1 year low of $3.31 and a 1 year high of $10.54.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Monday, October 29th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.06). On average, equities analysts forecast that Marinus Pharmaceuticals will post -0.93 EPS for the current year.

Several large investors have recently modified their holdings of the company. MetLife Investment Advisors LLC purchased a new position in shares of Marinus Pharmaceuticals during the third quarter worth approximately $292,000. Point72 Asset Management L.P. purchased a new position in shares of Marinus Pharmaceuticals during the third quarter worth approximately $670,000. Jane Street Group LLC purchased a new position in shares of Marinus Pharmaceuticals during the third quarter worth approximately $545,000. VHCP Management III LLC purchased a new position in shares of Marinus Pharmaceuticals during the third quarter worth approximately $6,723,000. Finally, VHCP Management II LLC increased its position in shares of Marinus Pharmaceuticals by 15.1% during the third quarter. VHCP Management II LLC now owns 397,236 shares of the biopharmaceutical company’s stock worth $3,972,000 after acquiring an additional 51,996 shares during the period. 68.70% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.

Featured Article: Why do company’s buyback their stock?

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.